Emyria Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Emyria is gedaald met een gemiddeld jaarlijks percentage van -22.7%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 35.4%. De inkomsten zijn groeide met een gemiddeld percentage van 20.7% per jaar.

Belangrijke informatie

-22.7%

Groei van de winst

-3.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	31.2%
Inkomstengroei	20.7%
Rendement op eigen vermogen	-472.3%
Nettomarge	-520.1%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Emyria geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ASX:EMD Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	2	-11	2	0
31 Mar 24	2	-12	2	0
31 Dec 23	2	-12	2	0
30 Sep 23	2	-9	2	0
30 Jun 23	2	-5	2	0
31 Mar 23	2	-6	2	1
31 Dec 22	2	-8	2	2
30 Sep 22	2	-7	3	2
30 Jun 22	2	-7	3	1
31 Mar 22	2	-7	3	1
31 Dec 21	2	-6	3	1
30 Sep 21	2	-6	2	1
30 Jun 21	2	-5	2	1
31 Mar 21	2	-5	2	1
31 Dec 20	2	-5	1	1
30 Sep 20	1	-5	2	1
30 Jun 20	1	-5	2	1
31 Mar 20	1	-5	2	1
31 Dec 19	1	-4	2	0
30 Sep 19	0	-3	2	0
30 Jun 19	0	-3	1	0

Kwaliteitswinsten: EMD is momenteel verliesgevend.

Groeiende winstmarge: EMD is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EMD is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 22.7% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EMD over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EMD is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 46.5% ).

Rendement op eigen vermogen

Hoge ROE: EMD heeft een negatief Return on Equity ( -472.33% ), omdat het momenteel verliesgevend is.

Emyria Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Recent updates

Emyria Limited, Annual General Meeting, Nov 12, 2024

New minor risk - Share price stability

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen